OIS Podcast | Ophthalmology's leading Podcast

OIS Podcast

Welcome to the Ophthalmology Innovation Podcast Where you get Candid Conversations with the Leaders and Drivers of Ophthalmic Innovation. OIS is the Largest and Original Producer of World-Class Ophthalmology Innovation Conferences and Content Since 2009.

read less
BusinessBusiness

Episodes

Building an Enterprise Under the Radar
03-11-2023
Building an Enterprise Under the Radar
Harrow isn’t a household name (yet), but eye care professionals have trusted its products for over a decade.The Nashville-based company produces Dexycu, an intraocular steroid; Iopidine for intraocular pressure control; and most recently, five Novartis products that Harrow acquired in December 2022.Rob Rothman, MD, caught up with Harrow founder and CEO Mark Baum to find out how he grew the company from worse than nothing—he acquired, restructured, and reorganized a company in bankruptcy in 2011—to a publicly traded organization with an enterprise value of $750 million.Baum describes Harrow as a “consortium of entrepreneurs.” That consortium includes:Eton Pharmaceuticals, developing products to treat rare diseaseSurface Ophthalmics, developing preservative-free products to treat dry eye disease and post-operative painMelt Pharmaceuticals, which produces MKO Melt, an FDA-approved analgesicHarrow built its business off compounded medications. By meeting needs of physicians in that way, it grew from zero to over 10,000 customers in a relatively short time.Looking ahead, Baum wants to build Harrow’s portfolio and its brand recognition, all while abiding by the company’s mission: to give patients access to affordable ophthalmic medications.Listen to the podcast today to discover:More about Baum’s career path, including his background as a lawyer and investor, his move into business, and the event that prompted him to reorganize and restructure what is now Harrow.Harrow’s corporate philosophy and why Baum considers the company a consortium of entrepreneurs.How Harrow grew from zero to over 10,000 customers in a few years.The secret to Harrow’s success, including how it profits from smaller, but no less important, assets.What’s next for Harrow, including the upcoming launch of Vevye, a dry eye drop based on Novaliq’s proprietary EyeSol water-free technology.How Harrow plans to grow within the next five years, and whether that includes developing its own products.ResourcesHarrow:                       harrow.comMark Baum:                marklbaum.com and on LinkedInRob Rothman, MD      ois.net/robert-rothman-md
Approachable Regenerative Medicine
20-10-2023
Approachable Regenerative Medicine
Endogena Therapeutics has developed a novel approach to regenerative medicine that’s not only scientifically compelling, but practical.Endogena’s technology unlocks the body’s own stem cells for controlled tissue repair by small molecules. Its products use a dosing schedule that could move easily into the system already in place for intravitreal injections.CEO Matthias Steger, PhD, MBA, sat down with retina specialist Firas Rahhal, MD, to discuss the Endogena approach in depth. They also discuss the compelling results seen so far in both animal models and in patients.The company’s lead candidate is being developed to treat retinitis pigmentosa. The product has received Orphan Drug and Fast Track Designation from the FDA and is moving through Phase IIa clinical trials. Dr. Steger says the company expects to have data to share in early 2024. It’s also submitting an investigational new drug (IND) application for an age-related macular degeneration treatment later this month.Listen to the podcast today to discover:The “serendipitous discoveries” that moved Dr. Steger’s career from applied science to financial analyst to regenerative medicine start-up cofounder.The stem cell approach that Dr. Steger and team are applying to Endogena products and how it differs from implanted stem cell programs.How Endogena applies its novel drug discovery approach to neurodegenerative retinal disease by rebuilding photoreceptors.The type and location of retinal stem cells used for Endogena treatments.The types of molecules used to stimulate or induce an effect from the stem cells.The incredible results the technology produced in mice—regenerating the outer retinal layer “nearly back to normal” and regenerating the rods and cones.The dosing schedule for the RP product and what happens after dosing is complete.How Endogena plans to fund its current and upcoming programs. Where has the funding come from to date? And for upcoming clinical trials?ResourcesEndogena Therapeutics          https://endogena.comFiras Rahhal, MD                     https://ois.net/firas-m-rahhal-md
The Bausch + Lomb Buzz, with Andrew Stewart and Yehia Hashad, MD
06-10-2023
The Bausch + Lomb Buzz, with Andrew Stewart and Yehia Hashad, MD
“You can see and feel a buzz within the company right now,” said Andrew Stewart, President, Global Pharmaceuticals and International Consumer, at Bausch + Lomb.Bausch + Lomb’s current momentum stems not only from new leadership, but also from recent collaborations, partnerships, and acquisitions.Stewart and Yehia Hashad, MD, Executive Vice President of Research & Development and Chief Medical Officer, join host Paul Karpecki, OD, to discuss these activities. Miebo, the first-in-class dry eye asset for the treatment of evaporative dry eye, tops the list.Looking ahead, Stewart and Dr. Hashad said the company is lasering its focus to tackle more unmet medical needs in eye care. The company intends to build on its legacy of innovation in drug delivery, in MOAs, and in developing new molecular entities.What’s next for the most recognized name in eye care?Topics discussed include:Why Stewart shifted into commercial from R&D, and why Dr. Hashad moved from clinical practice to R&D.How Bausch + Lomb leadership is looking at the future for a company with a 170-year legacy.Bausch + Lomb’s holistic approach to dry eye disease and treatment.The company’s thinking behind acquiring the rights from Novaliq to pursue development of what is now Miebo.The importance of addressing unmet needs with respect to the Bausch pipeline.What excites Dr. Hashad and Stewart about the company right now.Where they would like to see Bausch + Lomb in the next three to five years, including for Miebo, for ocular surface disease treatments, and for eye care.ResourcesMiebo                         https://www.miebo.comAndrew Stewart          https://www.bausch.com/about-bausch-lomb/leadership-teamYehia Hashad, MD       https://www.bausch.com/about-bausch-lomb/leadership-teamPaul Karpecki, OD       https://ois.net/paul-karpecki-od
C-Suite Quick Takes: OIS Goes Behind the Scenes with Four Emerging Biotech Companies
22-09-2023
C-Suite Quick Takes: OIS Goes Behind the Scenes with Four Emerging Biotech Companies
OIS Podcast host Carey Powers caught up with four ophthalmology execs and one principal investigator to talk about some of the most exciting developments in retina R&D.Her guests include:Houman David Hemmati, MD, PhD, Cofounder and Chief Medical Officer of Optigo Biotherapeutics   Michael Tsipursky, MD, CEO and Cofounder of Revive BiotechMichael Singer, MD, Clinical Professor of Ophthalmology at University of Texas Health Science Center, Director of Clinical Research at Medical Center Ophthalmology Associates, and Principal Investigator for Unity Biotechnology’s BEHOLD trialSamarendra Mohanty, PhD, President and Cofounder; and Sulagna Bhattacharya, CEO and Cofounder of Nanoscope TherapeuticsOptigo is developing binders intended to extend the duration of top-performing intravitreal drugs without compromising efficacy. The company has already had promising results in clinical trials with aflibercept. What’s next?Revive Biotech focuses on central retinal artery occlusion. Its products work by injecting oxygen-loaded nanobubbles into the eye intravitreally. Preclinical studies have advanced through proof of concept. Nanobubbles?Dr. Singer is a principal investigator in Unity Biotechnology’s clinical trial for UBX-1325, a therapeutic in development to treat diabetic macular edema and wet AMD. If approved, the product could work as an adjunct to anti-VEGF therapies.Nanoscope Therapeutics is developing gene therapies that focus on ambient light-sensitive molecules to treat inherited and acquired retinal diseases. Its lead product, MCO-010, is moving through Phase II trials. Why ambient light?Tune in to hear today’s experts discuss:How Optigo plans to extend the duration of afliberceptThe impact of extending duration activity on patients, physicians, and payersWhat Optigo plans to accomplish over the next 12 monthsWhat’s behind Revive Biotech’s proprietary technology and what makes it unique.The milestones it has completed so far with relation to clinical trials, intellectual property, and fundingThe new class of therapeutics being developed by Unity BiotechnologyThe data released so far on the UBX-1325 BEHOLD trialIf approved, the impact of UBX-1325—an agent that may potentially extend the life of anti-VEGF therapies—on clinical practiceThe potential impact of Nanoscope Therapeutics’s MCO-010 on patient communitiesThe feedback reported from clinical trial participantsThe critical milestones Nanoscope Therapeutics intends to achieve over the next year[Listen Now]
CEO Quick Takes
08-09-2023
CEO Quick Takes
OIS Podcast host Carey Powers speaks with four CEOs from leading retina-focus companies to talk about all things innovation. Her guests include:•  Kerrie Brady, BPharm, President and CEO of OcuTerra•  Rich Small, CEO of NeuroTech Pharmaceuticals•  Kester Nahen, PhD, CEO of Notal Vision•  Brad Doerschuk, President and CEO of InFocus ClinicalOcuTerra is developing OTT166, a novel small molecule designed to treat diabetic retinopathy.The product is getting attention because it can deliver product to the retina via an eye drop application, said Kerrie Brady, BPharm, CEO of OcuTerra.The company has completed enrollment for a Phase II trial in 225 patients with diabetic retinopathy. They hope to have topline results in early 2024.Next up: Rich Small, CEO of NeuroTech Pharmaceuticals. The company’s Encapsulated Cell Therapy (ECT) technology enables continuous production of therapeutic proteins to the eye.ECT is central to NT-501, a product being developed to treat macular telangiectasia (MacTel) as well as glaucoma.Third in line: Kester Nahen, PhD, CEO of Notal Vision. Notal Vision provides remote patient monitoring services for patients with retinal diseases. Its teleconnected devices use AI and analytics to give physicians insight into retinal activity in between patient visits. The company is also developing a home OCT device that has received Breakthrough Device designation from the FDA.Brad Doerschuk, CEO of InFocus Clinical, closes out the podcast by discussing the value of contracting with a specialist. He says InFocus is the first and only retina specialty CRO. The depth of ophthalmology expertise at the organization is hard to find, he says, and it enables the company to offer comprehensive, high-touch services to its clients.Other topics covered on today’s episode include:•  The mechanism of action of OcuTerra’s OTT166•  The opportunities that arise from a noninvasive local therapy and how this type of therapy could transform the standard of care.•  How NeuroTech’s ECT platform delivers proteins to the back of the eye.•  Details on NT-501’s Phase II and III studies.•  What 10 years of real-world data revealed about patients that use Notal Vision’s ForeseeHome.•  How Notal Vision’s Home OCT is helping clinical trial investigators.•  How Home OCT aids long-term treatment.•  What sets InFocus Clinical apart from other CROs that run ophthalmology studies.•  The latest additions to InFocus Clinical’s partnership program[Listen Now]ResourcesOcuTerra Therapeutics           ocuterratx.comNeuroTech                              neurotechpharmaceuticals.comNotal Vision                            notalvision.comInFocus Clinical                       infocusclinical.comCarey Powers:                          ois.net/carey-powersFor more on at-home OCT, give Episode #377 with Anat Loewenstein, MD, a listen. https://ois.net/the-latest-on-at-home-oct-with-anat-loewenstein-md